Human hematopoietic progenitors express low levels of O 6 -alkylguanine-DNA alkyltransferase and are sensitive to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), particularly following O 6 -benzylguanine (BG)-mediated O 6 -alkylguanine-DNA alkyltransferase inhibition. Expression of the BG-resistant mutant (G156A) methylguanine methyltransferase (⌬MGMT ) gene in hematopoietic cells confers resistance to BG and BCNU. Because BCNU targets both early and late human hematopoietic cells and results in prolonged and cumulative myelosuppression, we attempted to protect early hematopoietic progenitors (long-term culture initiating cells (LTC-ICs)) by retroviral-mediated transfer of the ⌬MGMT gene. A total of 33-56% of LTC-ICs were transduced with MFG-⌬MGMT retrovirus as determined by evidence of provirus in secondary colony-forming units at 5 weeks of culture under conditions optimal for the survival and proliferation of early hematopoietic progenitors. The addition of flt-3 ligand to cultures increased the transduction rate of LTC-ICs. Furthermore, 17.8 Ϯ 8.1% of ⌬MGMT-transduced LTC-ICs survived doses of BG and BCNU; these doses allowed the survival of only 0 -1% of untransduced LTC-ICs. This finding compares favorably with the 8 -12% of CD34 ϩ cell-derived colony-forming units that we previously showed became resistant to BG and BCNU after ⌬MGMT gene transfer. Thus, ⌬MGMT transduction of human early hematopoietic progenitor LTC-ICs confers resistance to BG and BCNU and may allow transduced LTC-ICs selective survival and enrichment over untransduced cells in patients undergoing BG and BCNU chemotherapy.
D
rug resistance gene transfer into hematopoietic progenitors is a proposed strategy to overcome the dose-limiting myelosuppression of chemotherapeutic agents. When drug resistance genes such as multidrug resistance gene-1 (MDR-1), dihydrofolate reductase (DHFR), and methylguanine methyltransferase (MGMT) are overexpressed in murine hematopoietic precursors, the number of transduced cells increases in hematopoietic tissue after paclitaxel, methotrexate, and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment, respectively, and the mice are protected from myelosuppression. [1] [2] [3] [4] [5] In humans, retroviral transfer of a number of genes into hematopoietic progenitors without drug treatment or other selection was shown to result in the stable integration and expression of the transgene in vivo, albeit at a low frequency. 6, 7 Clinical trials are underway to determine whether the number of MDR-1-transduced human hematopoietic progenitors can be increased in vivo following paclitaxel or doxorubicin treatments. 8 -10 Hematopoietic cells and, in particular, CD34 ϩ progenitors, contain low levels of O 6 -alkylguanine-DNA alkyltransferase (AGT), 11 explaining the common finding of dose-limiting, cumulative myelosuppression of chemotherapeutic agents that alkylate the O 6 position of guanine in DNA, such as nitrosoureas, dacarbazine, temozolomide, and procarbazine. We and others have investigated the role of the MGMT gene in transmitting nitrosourea resistance into hematopoietic progenitors following gene transfer. 5, 12, 13 The development of potent AGT inhibitors such as O 6 -benzylguanine (BG) stimulated the investigation of BG-resistant variants of AGT for drug resistance gene therapy. 14, 15 Mutant MGMT coding for an alanine in place of glycine at position 156 (⌬MGMT) can be efficiently introduced into mouse hematopoietic stem cells by an MFG-based retroviral vector; its product, G156A AGT, confers significant resistance to BG and BCNU both in vitro and in vivo. 4 This point mutation introduces steric hindrance into the active site pocket, reducing its reactivity with BG by 240-fold. 16 The relative protection against BG and BCNU provided with ⌬MGMT is significantly greater than that for BCNU provided by the overexpression of wild-type MGMT. Nitrosourea compounds are toxic to hematopoietic progenitors, causing prolonged and cumulative myelosuppression in patients. In addition, nitrosourea therapy is associated with marrow hypoplasia and secondary leukemias, 17 and there are animal models of nitrosourea-induced leukemogenesis 18 and marrow failure 19 providing indirect evidence that this group of agents damages stem cells. Therefore, an effective strategy to reduce nitrosourea-induced myelosuppression by drug resistance gene therapy requires the transduction of early progenitors. We have shown previously that human late hematopoietic progenitors (granulocyte-macrophage colony-forming units (GM-CFU) and erythroid burst-forming units) can be retrovirally transduced by ⌬MGMT and rendered resistant to BG and BCNU.
14 Recently, a number of conditions were identified that allow proliferation and retroviral transduction of earlier hematopoietic progenitors. These include the presence of stromal layer support, 20 early acting cytokines such as the flt-3 ligand (FL) 21 to keep primitive progenitors alive in vitro, and sufficient culture time to allow early progenitors to initiate progression through the cell cycle, thus enabling proviral integration. 22, 23 Although retroviral transduction of long-term culture initiating cells (LTCICs) by other drug resistance genes has been reported, these studies did not address the relative drug resistance at the level of these early progenitors. In the current study, we report a high efficiency of transduction of human LTC-ICs using transduction conditions that are most conducive to retroviral gene transfer into early hematopoietic progenitors based on the data from clinical trials and severe combined immunodeficiency repopulating cell assays. We show that human LTC-ICs are sensitive to BG and BCNU and can be protected by ⌬MGMT gene transfer.
MATERIALS AND METHODS

Retroviral vectors
The retroviral vector pMFG-⌬MGMT was constructed by inserting the G156A mutant human MGMT cDNA coding sequence into the unique NcoI and BamHI restriction sites of pMFG as described previously.
14 pMFG-⌬MGMT DNA was transfected into the packaging line GPϩE86, followed by viral supernatant infection of the amphotropic cell line GPϩenvAm12 24 (donated by Arthur Bank, Columbia University, New York, NY). To increase titer, a supernatant "pingpong" method was used. 25 The amphotropic CRIP MFGlacZ cell line was a generous gift of Paul Robbins (University of Pittsburgh, Pittsburgh, Pa). An expression titer of 3 ϫ 10 5 U/mL was estimated from cell-free, filtered supernatant collected after six daily media changes by infecting 1 ϫ 10 6 K562 cells as described below. Retroviral supernatant was shown to be free of helper virus by helper-rescue assay as described previously.
14
K562 transduction
The human chronic myelogenous leukemia cell line K562 was retrovirally transduced as described previously. 26 Briefly, ⌬MGMT producers were treated with 10 g/mL mitomycin C and replated. After 24 hours, K562 cells were added in the presence of human interleukin-3 (IL-3) (100 U/mL), human GM-CSF (200 U/mL), and polybrene (8 g/mL) and collected after a 48-hour coculture. In vitro selection of transduced K562 cells was performed by incubation in serum-free media containing 100 U/mL GM-CSF and 10 M BG at 37°C for 1 hour followed by 20 M of BCNU for 2 hours.
Transduction of peripheral blood CD34
ϩ cells 5 cells/ mL) were overlaid onto MFG-⌬MGMT or MFG-lacZ producers and cultured for 96 hours in Iscove's modified Dulbecco's medium containing 20% heat-inactivated fetal calf sera and protamine sulfate (4 g/mL, Sigma). Cultures were supplemented with combinations of human stem cell factor (SCF) (100 ng/mL, Amgen), megakaryocyte growth and differentiation factor (MGDF) (100 ng/mL, Amgen), IL-3 (100 U/mL, Sandoz, Basel, Switzerland), IL-6 (100 U/mL, Sandoz), and FL (100 ng/mL, Immunex, Seattle, Wash). After 48 hours, half of the medium was replaced. For retroviral supernatant infection over human stroma protocol, CD34 ϩ -enriched cells were prepared as described previously, resuspended in ⌬MGMT or lacZ retroviral supernatant collected from confluent producer cells as described previously, 26 and cultured in the presence of human bone marrow (BM) stroma. Allogeneic human BM stroma cultures were initiated as follows. BM MNCs were cultured in myeloid long-term culture medium (MyeloCult H5100 (StemCell Technologies, Vancouver, British Columbia, Canada) supplemented with 10 Ϫ6 M hydrocortisone) at 2 ϫ 10 6 cells/mL for 3 days at 37°C and 5% CO 2 , transferred to 33°C and 5% CO 2 , passaged once, and irradiated with 15 Gy ( 137 Cs) 24 hours before use. To infect CD34 ϩ cells, the cells were suspended in cell-free filtered retroviral supernatant at 1 ϫ 10 5 cells/mL, layered over the human stromal cells, and cultured at 37°C. Fresh retroviral supernatant and cytokines were added at 24-hour intervals. For both protocols, cells were removed from the stromal layer with cell dissociation buffer (Life Technologies, Gaithersburg, Md) after 96 hours; contaminating stromal cells were depleted by plastic adherence.
LTC-IC assay
Retrovirally transduced CD34 ϩ cells were cultured either in six-well plates (1 ϫ 10 4 to 5 ϫ 10 5 cells/well) or in 96-well plates (250 to 1 ϫ 10 4 cells/well) by suspension over near confluent adherent layers of allogeneic human BM stroma, prepared, and irradiated 1 day before the experiments as described previously. Cultures were maintained at 33°C and 5% CO 2 , and half of the medium (MyeloCult H5100 (StemCell Technologies) supplemented with 10 Ϫ6 M hydrocortisone) was changed weekly. Both nonadherent and adherent cells were harvested from 5-week-old cultures and transferred into com-plete methylcellulose media (StemCell Technologies) containing SCF, IL-3, hemin, erythropoietin, and GM-CSF 12 in duplicate. The complete cell content from each well of the six-well plates was cultured in 1 mL of complete methylcellulose media in 35-mm dishes, whereas all cells harvested from the individual wells of the 96-well plates were cultured in 24-well plates containing 0.5 mL/well of complete methylcellulose media. Progenitor colonies containing Ն50 cells were enumerated in 12-14 days, and a well that contained at least one progenitor colony was considered to be positive for the limiting dilution calculations of the LTC-IC frequency. The absolute number of LTC-ICs present in cell populations was estimated based on the positive wells of 96-well plates using Poisson statistics 27 or based on the number of CFUs per well of six-well plates, assuming that each LTC-IC gives rise to an average of four CFUs. 28 
In vitro drug treatment
Before long-term culture, CD34
ϩ -enriched cells were resuspended in serum-free media containing 100 U/mL GM-CSF with or without 10 M of BG and incubated at 37°C for 1 hour.
11 BCNU was added to the cells for 2 hours in serum-free media. 26 Cells were washed and cultured in 30% serumcontaining media supplemented with 5 M of BG.
Polymerase chain reaction (PCR) provirus analysis
DNA was isolated from single colonies as described previously. 26 A 440-base pair (bp) human MGMT fragment that amplifies only the provirus and not endogenous sequences and a 295-bp human dystrophin fragment were amplified and separated by 1.5% agarose gel and visualized by ethidium bromide staining. Alternatively, PCR products were visualized by hybridization with an MGMT sequence-specific digoxigenin probe and colorimetric detection using anti-digoxigenin-alkaline phosphatase and substrates nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim, Mannheim, Germany).
Fluorescence-activated cell sorter analysis for AGT expression
Cells were washed with phosphate-buffered saline-2% bovine serum albumin, fixed in 1% paraformaldehyde for 30 minutes on ice, and permeabilized in 1% Tween 20 for 30 minutes at 37°C. The samples were blocked with 10% normal goat sera for 30 minutes at room temperature, resuspended in phosphate buffered saline-2% bovine serum albumin, and incubated overnight at 4°C with 1 g of the AGT monoclonal antibody mT3.1 (kindly provided by Drs. D. Bigner (Duke University, Durham, NC) and T. Brent (St. Jude Children's Hospital, Memphis, Tenn) or immunoglobulin Gk isotype as described previously. 29 The samples were incubated with goat antimouse antibody conjugated to phycoerythrin (PharMingen, San Diego, Calif) for 1 hour on ice. Flow cytometry was performed using a FACScan (Becton Dickinson, Mountain View, Calif), and data were analyzed by CellQuest software (Becton Dickinson).
Northern blot analysis
Total RNA was isolated from ⌬MGMT-transduced K562 cells using Trizol Reagent (Life Technologies). A total of 10 g of total RNA was separated by electrophoresis on a 1.5% agarose gel containing formaldehyde, transferred to a nylon membrane, and subjected to hybridization with a 32 P-random primer-labeled MGMT cDNA BamHI fragment. The sizes of the ⌬MGMT transcripts were estimated based on 28S and 18S ribosomal RNA.
RESULTS
Frequency and in vitro maintenance of LTC-ICs
In five independent experiments, the G-CSF-mobilized CD34 ϩ -enriched peripheral blood cells of normal human subjects contained a mean of 0.52% Ϯ 0.12 LTCICs immediately after processing and 0.11% Ϯ 0.14 LTC-ICs following the 96-hour retroviral infection protocol ( Table 1 ). The 5-fold reduction in the concentration of LTC-ICs was mostly due to expansion of the MNCs in culture, and an average of 50% Ϯ 32 of the LTC-ICs were recovered at the end of the retroviral infection period.
⌬MGMT transduction of the LTC-ICs
G-CSF-mobilized CD34
ϩ cell-enriched peripheral blood cells containing a mean of 57% CD34 ϩ cells were exposed to the retrovirus using either the coculture or supernatant over human stroma protocols. Both protocols used an infection period of 96 hours with no prestimulation period and were supplemented with FL, IL-6, IL-3, and SCF. In two experiments using supernatant over human stroma protocol, the additional cytokine cocktails tested were: (a) FL, IL-6, and SCF; (b) IL-3, IL-6, and SCF; and (c) FL and MGDF; concentrations are indicated in Materials and Methods. Following retroviral infection, long-term myeloid cultures were initiated; at the end of the 5-week culture period, both adherent and nonadherent cells were plated onto methylcellulose. Individual secondary CFUs were picked and analyzed for the presence of proviral sequences by PCR (Fig 1) . Retroviral transduction of the LTC-ICs was inferred from the transduction frequency of the secondary CFUs. The overall transduction rate of the secondary CFUs was 44% (74/169) ( Table 1) , and no significant difference was observed between coculture and supernatant over human stroma protocols. The effect of the cytokine cocktail on the transduction rate of primary (2 weeks) and secondary (7 weeks) CFUs was examined in experiments using the retroviral supernatant over human stroma protocol (Fig 2) . There was a significant decrease in the transduction rate of the secondary CFUs when CD34 ϩ cells were cultured in IL-3, IL-6, and SCF (28%) compared with IL-3, IL-6, SCF, and FL (51%, P ϭ .035, Fisher's exact test). When all three FLcontaining combinations were compared with the IL-3, IL-6, and SCF combination, there was a trend toward an increased transduction rate (P ϭ .08, Fisher's exact test).
AGT expression Flow-cytometric detection of AGT-overexpressing cells was performed on freshly infected CD34
ϩ cells using a technique to identify intracellular AGT immunostaining as described previously. In each experiment, ⌬MGMT transduction of the CD34 ϩ cells resulted in a distinct subpopulation of cells with increased immunoreactive AGT expression (Fig 3) . ⌬MGMT-transduced cells had a mean fluorescence intensity of 105 Ϯ 54, compared with 14 Ϯ 4 (P ϭ .007) for lacZ-transduced cells. To determine the transcriptional integrity of the ⌬MGMT provirus, we performed a Northern blot analysis using K562 cells transduced with the same MFG-⌬MGMT retrovirus used to infect primary human CD34 ϩ cells. We detected the expected 2.5-kilobase (kb) full-length and 1.5-kb spliced proviral ⌬MGMTmRNA in ⌬MGMT-transduced K562 cells (Fig 4) . Furthermore, the mRNA is signifi- cantly more abundant in ⌬MGMT-transduced K562 cells after BG and BCNU selection.
Drug resistance in human LTC-ICs Following the 96-hour retroviral infection, CD34
ϩ cells were treated with 10 M of BG for 1 hour followed by BCNU (0 -20 M) for 2 hours, after which long-term myeloid cultures were initiated. On the first day of the LTC, cells were exposed to additional BG (5 M) to maintain AGT inhibition for an additional 18 -24 hours after BCNU treatment, which is critical to maximizing BG potentiation of BCNU in the absence of ⌬MGMT. 30, 31 Secondary CFU output after 5 weeks was reduced to almost 0 in cultures initiated after lacZ transduction and drug treatment ( Table 2 ). In contrast, ⌬MGMT-transduced LTC-ICs gave rise to secondary CFUs, even after exposure to 20 M of BCNU, yielding survival of 17.8 Ϯ 8.1% of ⌬MGMT-transduced LTCICs after 10 M of BG and 7.5-20 M of BCNU compared with Յ1% of the lacZ-transduced LTC-ICs. Furthermore, the frequency of transduction in the secondary CFUs harvested from cultures treated with BG and BCNU was significantly higher than that seen for the CFUs harvested from cultures that were not drugtreated, reaching 100% in some cultures (Table 2) .
DISCUSSION
Our results indicate that human early hematopoietic progenitors, LTC-ICs, are sensitive to BCNU in the presence of the AGT inhibitor BG. These results are similar to those that we obtained with late progenitor GM-CFUs and erythroid burst-forming units, 14 and provide further evidence that BCNU is toxic to early progenitors, explaining the prolonged and cumulative myelosuppression observed with this agent in clinical trials. This finding is in sharp contrast to the in vitro 5-fluorouracil treatment of human BM cells that resulted in the killing of CFUs but not the earlier progenitors, as evidenced by the recovery of up to 89% LTC-ICs. 32, 33 Other antimetabolites such as cytosine arabinoside and methotrexate have also been shown to spare primitive CFU-spleen preferentially over more mature CFUs in the mouse. 34 The relative antifolate resistance of murine CFU-spleen was thought to be due to cell cycle dormancy, although more recent evidence suggests that thymidine import from the extracellular environment is an important resistance mechanism against antifolates. 35 Cytotoxic agents that are P-glycoprotein substrates are also less toxic to early hematopoietic progenitors than late progenitors. P-glycoprotein expression was shown to correlate with high CD34 expression and a high clonogenic capacity of hematopoietic progenitors. 36 Rhodamine dull CD34 ϩ cells were shown to be 2-to 3-fold less sensitive to anthracyclines A total of 10 g of total RNA was loaded from both cell populations. The higher band represents the 2.5-kb full-length proviral ⌬MGMT mRNA probed with 32 P-labeled ⌬MGMT cDNA. The lower band corresponds to the 1.5 kb of spliced proviral ⌬MGMT mRNA. compared with rhodamine bright cells, indicating the relative resistance of more primitive cells. 37 For successful drug selection of transduced hematopoietic clones, it is important to provide drug resistance to progenitors earlier than CFUs. The relative resistance provided to CFUs with DHFR or MDR-1 gene transfer may not apply to earlier progenitors with intrinsic resistance against antimetabolites and P-glycoprotein substrates. Therefore, successful drug selection with these agents relies on a high efficiency of transduction and high expression at the level of early progenitors to compete with the intrinsic resistance. In contrast, our results show that early human hematopoietic progenitors are as sensitive to nitrosourea treatment as late progenitors. This observation allowed us to demonstrate relative BG and BCNU resistance at the LTC-IC level by ⌬MGMT gene transfer that was comparable with that obtained in CFUs.
We efficiently transduced human LTC-ICs by the retroviral vector MFG-⌬MGMT in five different experiments using a variety of cytokines and transduction protocols and observed that 33-56% of the secondary CFUs contained the provirus 7 weeks after the retroviral infection. These transduction rates compare favorably with other studies aimed at retroviral transduction of LTC-ICs. 38 -40 We optimized transduction conditions by combining the supporting stromal layer in the form of either murine producer cells (coculture) or allogeneic human stroma (supernatant over stroma) with multiple hematopoietic cytokines. Of the cytokines used, FLcontaining cocktails increased the transduction efficiency of the early hematopoietic progenitors over the IL-3, IL-6, and SCF combination. There was no significant difference in LTC-IC transduction efficiency among the cytokine cocktails containing FL. Interestingly, the FL and MGDF combination was as effective as the FL, IL-3, IL-6, and SCF combination, suggesting that MGDF can replace IL-3, IL-6, and SCF in the presence of a stromal layer. A prolonged (96-hour) transduction period was chosen to allow cycling of the early progenitors under the influence of stromal cells and cytokines and may have contributed to the high transduction efficiency we routinely observed.
At the end of the 96-hour transduction, LTC-ICs were resistant to BG and BCNU as evidenced by significant secondary CFU output at 5 weeks, indicating expression of the mutant AGT in these early progenitors at least at the start of the culture period. A total of 12-30% of the transduced secondary CFUs survived the drug treatment. This proportion is similar to that observed for our published studies with primary CFUs, in which ϳ25% of the transduced CFUs were drug-resistant. 14 Our results indicate that transduction of the ⌬MGMT gene is not sufficient in some cells to render them BG-and BCNUresistant. This is commonly observed in retroviral transduction studies of primary cells. We have shown that the vector we used to infect CD34 ϩ cells is efficiently expressed in K562 cells, making any significant rearrangement or deletion in the vector unlikely. We postulate that in some hematopoietic progenitors, ⌬MGMT is inserted into transcriptionally inactive sites and therefore does not render them BG-and BCNU-resistant despite positivity for the proviral sequences by PCR. In addition, at the time of drug selection, which was shortly after retroviral infection, some transduced LTC-ICs may not be expressing sufficient proviral mRNA to provide resistance. Furthermore, ⌬MGMT-transduced LTC-ICs were enriched in vitro by BG and BCNU treatment, because the frequency of the provirus-positive secondary CFUs obtained from drug-treated cultures was significantly higher than in the untreated cultures. Following BG and BCNU treatment, all surviving secondary CFUs of donor 1 and 73-90% of surviving CFUs of donor 2 were PCR-positive for ⌬MGMT ( Table 2 ). The degree 41 This observation further supports the concern that simply overexpressing wild-type AGT in these cells would not offer protection against BG and BCNU.
Drug resistance genes have been transferred previously into human LTC-ICs, 42, 43 but the ability to provide selective drug resistance over untransduced LTC-ICs has not been evaluated carefully. Flasshove et al 43 showed an ϳ2-fold selection advantage for pre-CFUs transduced with a mutant DHFR and exposed to methotrexate. In these experiments, 80% of the untransduced pre-CFUs survived the drug treatment; therefore, the stringency of drug selection could not be assessed accurately. In contrast, ⌬MGMT gene transfer resulted in the survival of Ͼ15% of LTC-ICs at BG and BCNU concentrations that allowed Ͻ1% survival of the untransduced LTC-ICs. This degree of resistance (15-fold) is similar to that observed with ⌬MGMT-transduced CFUs, indicating that BG and BCNU selection is as stringent for the early progenitors as it is for more differentiated ones.
Efficient retroviral transduction of human hematopoietic stem cells remains challenging. The quiescence and low levels of amphotropic receptor expression 44 of these cells seem to be major limiting factors. Despite these limitations, recent evidence suggests that the severe combined immunodeficient mouse repopulating cell, an earlier progenitor than the LTC-IC, can be retrovirally transduced under conditions similar to the ones reported here. Although efficient transduction of the LTCICs does not necessarily predict transduction of the stem cells, our results suggest that if a stem cell is transduced by ⌬MGMT, it is likely that it will provide selective survival advantage against BG and BCNU over untransduced stem cells. In fact, in murine models, we have observed that as few as 50,000 ⌬MGMT-transduced mouse BM cells can be selectively expanded when infused into a nonmyeloablated host that was then treated with BG and BCNU. 4 The lack of significant enrichment of the MDR-1-transduced hematopoietic cells in the current clinical trials may be due to both low transduction efficiency of the stem cells and a lack of significant selective advantage for the transduced stem cells over untransduced ones following drug therapy. 45 Our results suggest that ⌬MGMT may result in selective enrichment of the transduced stem cells due to the exquisite sensitivity of these cells to BG and BCNU and to the 15-fold protection with mutant AGT.
In conclusion, we have demonstrated that BG and BCNU treatment is toxic to early human hematopoietic progenitors (LTC-IC), and that high-efficiency ⌬MGMT gene transfer into these cells results in the expression of a BG-resistant AGT, resulting in resistance to BG and BCNU. We plan to test whether transduced early human hematopoietic progenitors contribute to hematopoiesis in vivo, and whether they can be selectively enriched after infusion into patients receiving BG and BCNU chemotherapy.
